Toxoplasmosis in the compromised host.
Toxoplasmosis in the compromised host.
复制标题
受损宿主中的弓形虫病。
DOI：
10.7326/0003-4819-84-2-193
复制
发表时间：
1976
影响因子：
39.2
通讯作者：
J. Remington
中科院分区：
文献类型：
--
作者：
J. Ruskin;J. Remington
在81例弓形虫病患者的肿瘤，胶原血管疾病，器官移植，临床表现是高度可变的，但神经系统综合征符合弥漫性脑病，脑膜脑炎，或脑肿块病变占主导地位。观察到许多DNA病毒伴随感染。弓形虫病的诊断，直到尸检在大多数情况下。淋巴结或脑活检和血清学试验需要明确的诊断很少。20例患者接受抗弓形虫化疗（乙胺嘧啶和磺胺），16例（80%）表现出显着的临床改善或完全缓解。在免疫抑制的宿主中，播散性弓形虫病似乎是由于细胞免疫缺陷导致潜伏感染复发。由于细胞介导的免疫力，以弓形虫可以增强动物的佐剂，免疫治疗可能成为一个有用的辅助化疗免疫功能低下的人遭受潜在的致命感染。
In 81 cases of toxoplasmosis in patients with neoplasia, collagen-vascular disorders, and organ allografts, the clinical manifestations were highly variable but neurologic syndromes consistent with diffuse encephalopathy, meningoencephalitis, or cerebral mass lesions predominated. Many concomitant infections with DNA viruses were seen. The diagnosis of toxoplasmosis was not made until postmortem examination in most cases. Biopsy of lymph nodes or brain and serologic tests needed for definitive diagnosis were done infrequently. Twenty patients received antitoxoplasma chemotherapy (pyrimethamine and sulfonamide), 16 (80%) showing marked clinical improvement or complete remission. In immunosuppressed hosts disseminated toxoplasmosis appears to result from defects in cellular immunity that permit recrudescence of latent infection. Because cell-mediated immunity to Toxoplasma gondii can be enhanced in animals by administration of adjuvants, immunotherapy may become a useful adjunct to chemotherapy in immunoincompetent humans suffering potentially lethal infection.